MCID: FST001
MIFTS: 39

Foster-Kennedy Syndrome

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Foster-Kennedy Syndrome

MalaCards integrated aliases for Foster-Kennedy Syndrome:

Name: Foster-Kennedy Syndrome 12 15 17 71
Disorder of the Optic Nerve 71
Optic Nerve Diseases 44

Classifications:



External Ids:

Disease Ontology 12 DOID:14555
ICD9CM 34 377.04
MeSH 44 D009901
SNOMED-CT 67 87764000
ICD10 32 H47.14
UMLS 71 C0029132 C0152112

Summaries for Foster-Kennedy Syndrome

MalaCards based summary : Foster-Kennedy Syndrome, also known as disorder of the optic nerve, is related to meningioma, familial and spinal meningioma, and has symptoms including sciatica and eye manifestations. An important gene associated with Foster-Kennedy Syndrome is SDHAF2 (Succinate Dehydrogenase Complex Assembly Factor 2), and among its related pathways/superpathways are Prion disease and Carbon metabolism. The drugs Bevacizumab and 4-Aminopyridine have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, eye and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 74 Foster Kennedy syndrome is a constellation of findings associated with tumors of the frontal... more...

Related Diseases for Foster-Kennedy Syndrome

Diseases related to Foster-Kennedy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 meningioma, familial 10.7
2 spinal meningioma 10.7
3 secretory meningioma 10.7
4 lymphoplasmacyte-rich meningioma 10.7
5 3-methylglutaconic aciduria, type iii 10.6
6 papilledema 10.5
7 optic nerve disease 10.5
8 nonarteritic anterior ischemic optic neuropathy 10.5
9 spinal arachnoiditis 10.4
10 arachnoiditis 10.4
11 olfactory groove meningioma 10.4
12 intracranial hypertension 10.4
13 posttransplant acute limbic encephalitis 10.4
14 retinal disease 10.2
15 arteritic anterior ischemic optic neuropathy 10.2
16 optic neuritis 10.2
17 neuritis 10.2
18 pituitary adenoma 10.2
19 adenoma 10.2
20 neuropathy 10.2
21 juvenile nasopharyngeal angiofibroma 10.2
22 microvascular complications of diabetes 5 10.1
23 autoimmune disease 10.1
24 optic nerve hypoplasia, bilateral 10.1
25 spondylosis, cervical 10.1
26 temporal arteritis 10.1
27 hydrocephalus due to congenital stenosis of aqueduct of sylvius 10.1
28 retinitis pigmentosa 10.1
29 yemenite deaf-blind hypopigmentation syndrome 10.1
30 homocysteinemia 10.1
31 nasopharyngeal carcinoma 10.1
32 vitamin b12 deficiency 10.1
33 neuroretinitis 10.1
34 malignant hypertension 10.1
35 hydrocephalus 10.1
36 hemiplegia 10.1
37 arteriovenous malformation 10.1
38 telangiectasis 10.1
39 echinococcosis 10.1
40 retinal vein occlusion 10.1
41 spondylosis 10.1
42 high grade glioma 10.1
43 demyelinating disease 10.1
44 mammary paget's disease 10.1
45 retinitis 10.1
46 plasmacytoma 10.1
47 peripheral nervous system disease 10.1
48 cataract 10.1
49 neuromyelitis optica 10.1
50 scotoma 10.1

Graphical network of the top 20 diseases related to Foster-Kennedy Syndrome:



Diseases related to Foster-Kennedy Syndrome

Symptoms & Phenotypes for Foster-Kennedy Syndrome

UMLS symptoms related to Foster-Kennedy Syndrome:


sciatica, eye manifestations

GenomeRNAi Phenotypes related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.32 SDHC
2 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.32 SDHC
3 Increased shRNA abundance (Z-score > 2) GR00366-A-141 9.32 SDHD
4 Increased shRNA abundance (Z-score > 2) GR00366-A-142 9.32 SDHC
5 Increased shRNA abundance (Z-score > 2) GR00366-A-153 9.32 SDHC
6 Increased shRNA abundance (Z-score > 2) GR00366-A-188 9.32 SDHC SDHD
7 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.32 SDHC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-55 9.32 SDHC
9 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.32 SDHC

MGI Mouse Phenotypes related to Foster-Kennedy Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.02 MIB1 SDHA SDHAF2 SDHC SDHD

Drugs & Therapeutics for Foster-Kennedy Syndrome

Drugs for Foster-Kennedy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
4-Aminopyridine Approved Phase 4 504-24-5 1727
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Carbidopa Approved Phase 4 28860-95-9 34359
6
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
7
Choline Approved, Nutraceutical Phase 4 62-49-7 305
8 Cytidine Diphosphate Choline Phase 4
9 Angiogenesis Inhibitors Phase 4
10 Antineoplastic Agents, Immunological Phase 4
11 Potassium Channel Blockers Phase 4
12 Dopamine Agents Phase 4
13 Antiparkinson Agents Phase 4
14 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
15 Dopamine agonists Phase 4
16 Adjuvants, Immunologic Phase 4
17 Immunologic Factors Phase 4
18 Carbidopa, levodopa drug combination Phase 4
19 Phosphodiesterase 5 Inhibitors Phase 4
20 Sildenafil Citrate Phase 4 171599-83-0
21 Vardenafil Dihydrochloride Phase 4
22
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
23
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
24 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
25
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
26
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
27
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
28
Bosentan Approved, Investigational Phase 3 147536-97-8 104865
29
Curcumin Approved, Experimental, Investigational Phase 3 458-37-7 969516
30
Bezafibrate Approved, Investigational Phase 2, Phase 3 41859-67-0 39042
31
Linezolid Approved, Investigational Phase 3 165800-03-3 441401
32
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
33 Triamcinolone hexacetonide Phase 3
34 triamcinolone acetonide Phase 3
35 Triamcinolone diacetate Phase 3
36 Methylprednisolone Acetate Phase 3
37 Neuroprotective Agents Phase 3
38 Immunosuppressive Agents Phase 3
39 Antihypertensive Agents Phase 3
40 Endothelin Receptor Antagonists Phase 3
41 Anti-Inflammatory Agents Phase 3
42 Antirheumatic Agents Phase 3
43 Analgesics, Non-Narcotic Phase 3
44 Anti-Inflammatory Agents, Non-Steroidal Phase 3
45 Analgesics Phase 3
46 Lipid Regulating Agents Phase 2, Phase 3
47 Antimetabolites Phase 2, Phase 3
48 Hypolipidemic Agents Phase 2, Phase 3
49 Hematinics Phase 3
50 Epoetin alfa Phase 3 113427-24-0

Interventional clinical trials:

(show top 50) (show all 98)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Evaluation of Neural Conduction Along the Visual Pathways Before and After Oral Treatment With Citicoline in Patients With Optic Nerve Diseases Completed NCT00404729 Phase 4 Citicoline
2 Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Completed NCT01975324 Phase 4 dalfampridine;Placebo
3 Effect of Levodopa-Carbidopa on Visual Function in Patients With Recent-Onset Nonarteritic Anterior Ischemic Optic Neuropathy Completed NCT00432393 Phase 4 levodopa-carbidopa
4 Use of Bevacizumab in Trabeculectomy Surgery. A Prospective, 2 Centre, Randomized, Controlled Trial Completed NCT01166594 Phase 4 Bevacizumab;Control
5 Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study Completed NCT03046693 Phase 4 Group A Citicoline 1000 mg oral tablet;Group B placebo oral tablet
6 External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON) Active, not recruiting NCT02774005 Phase 4 Idebenone
7 Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT00867815 Phase 4 Diagnostic procedures
8 The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial Unknown status NCT02439866 Phase 3 placebo;Intravenous methylprednisolone;normobaric oxygen with face mask
9 Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy Unknown status NCT02377271 Phase 3 bosentan;placebo
10 Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT02329288 Phase 3 Triamcinolone Acetonide;placebo
11 Ischemic Optic Neuropathy Decompression Trial (IONDT) Completed NCT00000127 Phase 3
12 A Randomized, Double-blind, Placebo-controlled Trial of Curcumin in Leber's Hereditary Optic Neuropathy (LHON) Completed NCT00528151 Phase 3 curcumin
13 Study of Efficacy of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy Recruiting NCT04561466 Phase 2, Phase 3 Béfizal
14 Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT Recruiting NCT03308448 Phase 3 Recombinant human erythropoietin
15 Erythropoietin in Methanol Associated Optic Neuropathy Active, not recruiting NCT02376881 Phase 3 Erythropoietin
16 Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year Active, not recruiting NCT03293524 Phase 3 Placebo
17 Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials Active, not recruiting NCT03406104 Phase 3
18 A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy Active, not recruiting NCT03153293 Phase 2, Phase 3 rAAV2-ND4
19 Prospective Study Of Ophthalmologic Function In Patients Receiving Linezolid For Six Weeks Or Greater Terminated NCT00359632 Phase 3 Zyvox - linezolid;Matched control
20 A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Terminated NCT02341560 Phase 2, Phase 3 QPI-1007 Injection - 1.5 mg;QPI-1007 Injection - 3.0 mg
21 Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON) Withdrawn NCT01495715 Phase 3 Idebenone;Placebo
22 Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease. It is Self Funded (Patients' Own Funding) Clinical Trial Unknown status NCT01834079 Phase 1, Phase 2
23 Comparison of Intravitreal Bevacizumab and Triamcinolone With Placebo in Acute Nonarteritic Anterior Ischemic Optic Neuropathy Unknown status NCT01330524 Phase 1, Phase 2 Avastin and Triamcinolone
24 Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy Unknown status NCT02176733 Phase 2 cyclosporine
25 Intravitreal Bevacizumab for Treatment of the Second Eye With Non-Arteritic Ischemic Optic Neuropathy Unknown status NCT00813059 Phase 2 Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)
26 Prospective, Unicentric, Randomized, Parallel, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate Intravenous Infusion of Prostaglandins as Therapy in Patients With Anterior Non-arteritic Ischemic Optic Neuropathy Unknown status NCT03851562 Phase 2 Alprostadil 20 micrograms;Placebo
27 Scientific Title: Efficacy of Oral Prednisolone and Erythropoietin Injection in Treatment of Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Unknown status NCT03715881 Phase 2 Oral prednisolone administration 50 mg;Intravenous Erythropoietin injection
28 An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene Completed NCT02064569 Phase 1, Phase 2
29 A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON) Completed NCT02693119 Phase 2 elamipretide (MTP-131) 1% topical ophthalmic solution;Vehicle topical ophthalmic solution
30 Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON) Completed NCT01783847 Phase 1, Phase 2 Recombinant human erythropoietin (EPO);Methyl prednisolone
31 Neurotomy of Optic Nerve in Non-Arthritic Anterior Ischemic Optic Neuropathy Completed NCT00372021 Phase 1, Phase 2
32 A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION). Completed NCT02045212 Phase 2 RPh201;Placebo
33 A Double-Blind, Randomised, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Patients With Leber's Hereditary Optic Neuropathy Completed NCT00747487 Phase 2 Idebenone;Placebo
34 A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis Recruiting NCT03536559 Phase 2 CNM-Au8;Placebo
35 Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study Recruiting NCT02638714 Phase 1, Phase 2
36 Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION) Recruiting NCT03173638 Phase 2
37 Studying the Effect of Subcutaneous Injection of Erythropoietin in Patients With Recent Onset Indirect Traumatic Optic Neuropathy. Active, not recruiting NCT04469777 Phase 1, Phase 2 erythropoietin
38 A Double-Masked Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Participants With Previous NAION Terminated NCT03547206 Phase 2 RPh201 Cohort A;RPh201 Cohort B
39 Near-infrared Light-emitting Diode (NIR-LED) Therapy for Leber's Hereditary Optic Neuropathy (LHON) Terminated NCT01389817 Phase 1, Phase 2
40 Spectral Domain Optical Coherence Tomography Imaging of the Eyes of Neonates Completed NCT01404247 Phase 1
41 NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and Neuroenhancement Completed NCT01411657 Phase 1 NT-501 CNTF Implant
42 Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION) Completed NCT00561834 Phase 1 ranibizumab
43 A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II) Completed NCT01064505 Phase 1 QPI-1007 at various doses
44 An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA Active, not recruiting NCT02161380 Phase 1 injection of scAAV2-P1ND4v2 1.18x10e9 vg (Low),;injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med);injection of scAAV2-P1ND4v2 2.4 X10e10vg (High);injection of scAAV2-P1ND4v2 1.0 X10e11vg (Higher)
45 Can Urgent Reduction of Intraocular Pressure With Ophthalmic Timolol Improve Recovery From Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): a Randomized Study. Withdrawn NCT01607671 Phase 1 Timolol maleate
46 A Prospective Single Institution Study of Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab Unknown status NCT01331616 Early Phase 1 Bevacizumab (Avastin)
47 Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study Unknown status NCT02711982 methylprednisolone
48 Ischemic Optic Neuropathy Decompression Trial Followup (IONDT Followup) Unknown status NCT00000126
49 Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy Unknown status NCT01768260 Aspirin
50 Near to Infrared Light Stimulation Effect on Ganglion Cell Function in Glaucomatous Optic Neuropathy Unknown status NCT00844389 Early Phase 1

Search NIH Clinical Center for Foster-Kennedy Syndrome

Cochrane evidence based reviews: optic nerve diseases

Genetic Tests for Foster-Kennedy Syndrome

Anatomical Context for Foster-Kennedy Syndrome

MalaCards organs/tissues related to Foster-Kennedy Syndrome:

40
Bone Marrow, Eye, Bone, Endothelial, Retina, Pituitary, Cortex

Publications for Foster-Kennedy Syndrome

Articles related to Foster-Kennedy Syndrome:

(show top 50) (show all 327)
# Title Authors PMID Year
1
Hyperhomocysteinemia and low folate levels as the only risk factors in pseudo-Foster Kennedy syndrome. 61
33608175 2021
2
Plexus-specific retinal vascular anatomy and pathologies as seen by projection-resolved optical coherence tomographic angiography. 61
32712135 2021
3
Umbilical cord-derived mesenchymal stem cell implantation in patients with optic atrophy. 61
33307808 2020
4
Diagnostic performance of multifocal photopic negative response, pattern electroretinogram and optical coherence tomography in glaucoma. 61
32926894 2020
5
Bruch's Membrane Opening Minimum Rim Width Provides Objective Differentiation between Glaucoma and Nonglaucomatous Optic Neuropathies. 61
32574771 2020
6
Compressive Optic Disc Edema and Contralateral Papilledema: Type 2 Foster Kennedy Variant Syndrome. 61
33105415 2020
7
In vivo evaluation of retinal ganglion cells and optic nerve's integrity in large animals by multi-modality analysis. 61
32598972 2020
8
Umbilical Cord Blood and Serum for the Treatment of Ocular Diseases: A Comprehensive Review. 61
32107737 2020
9
Bilateral epiretinal membrane formation following intravitreal injections of autologous mesenchymal stem cells. 61
32568958 2020
10
Giant Pituitary Adenoma Presenting with Foster-Kennedy Syndrome in a 21-Year Old Ethiopian Patient: A Rarely Reported Phenomenon: A Case Report. 61
32165821 2020
11
Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration. 61
32231088 2020
12
Choroidal Vascularity Index: An In-Depth Analysis of This Novel Optical Coherence Tomography Parameter. 61
32098215 2020
13
[Protocol of intravitreal drug delivery. Consensus of the Expert Counsil of Retina and Optic Nerve Diseases of the All-Russian Public Organasation «Association of Ophthalmologists»]. 61
33371657 2020
14
Pseudo-Foster Kennedy syndrome due to idiopathic intracranial hypertension. 61
31635921 2019
15
Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study. 61
31309439 2019
16
Genome-wide association analysis of 95 549 individuals identifies novel loci and genes influencing optic disc morphology. 61
31809533 2019
17
Foster-Kennedy Syndrome. 61
31227267 2019
18
[Foster Kennedy syndrome secondary to a large meningioma]. 61
31130385 2019
19
Traditional two-dimensional mesenchymal stem cells (MSCs) are better than spheroid MSCs on promoting retinal ganglion cells survival and axon regeneration. 61
31202832 2019
20
Foster Kennedy syndrome. 61
30690544 2019
21
Pheochromocytoma, paragangliomas, and pituitary adenoma: An unusual association in a patient with an SDHD mutation. Case report. 61
31348302 2019
22
Foster Kennedy Syndrome. 61
31238653 2019
23
A Unique Case of Sinonasal Teratocarcinosarcoma Presenting as Foster Kennedy Syndrome. 61
31084671 2019
24
Chromatic Pupillometry Methods for Assessing Photoreceptor Health in Retinal and Optic Nerve Diseases. 61
30809186 2019
25
Effective Delivery of Exogenous Compounds to the Optic Nerve by Intravitreal Injection of Liposome. 61
30311465 2018
26
Serotype survey of AAV gene delivery via subconjunctival injection in mice. 61
30072815 2018
27
Ganglion cell-inner plexiform layer thickness by swept-source optical coherence tomography in healthy Korean children: Normative data and biometric correlations. 61
30006534 2018
28
Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. 61
29852910 2018
29
[Hereditary Optic Neuropathies]. 61
29490390 2018
30
An overview of the clinical applications of optical coherence tomography angiography. 61
28885606 2018
31
Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. 61
29552298 2018
32
The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration. 61
30524222 2018
33
Progress in Gene Therapy to Prevent Retinal Ganglion Cell Loss in Glaucoma and Leber's Hereditary Optic Neuropathy. 61
29853847 2018
34
Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of Retinitis Pigmentosa. 61
30050918 2018
35
Safety of high-dose intravitreal triamcinolone acetonide as low-cost alternative to anti-vascular endothelial growth factor agents in lower-middle-income countries. 61
30538421 2018
36
Retinal changes in diabetic patients without diabetic retinopathy. 61
29516043 2017
37
A Promising Tool in Retina Regeneration: Current Perspectives and Challenges When Using Mesenchymal Progenitor Stem Cells in Veterinary and Human Ophthalmological Applications. 61
28643176 2017
38
Evidence for Cerebrospinal Fluid Entry Into the Optic Nerve via a Glymphatic Pathway. 61
28973323 2017
39
Mitochondrial dynamics, transport, and quality control: A bottleneck for retinal ganglion cell viability in optic neuropathies. 61
28866056 2017
40
Unilateral Papilledema in Cerebral Venous Sinus Thrombosis. 61
28936083 2017
41
Optical Coherence Tomography Angiography: A New Tool in Glaucoma Diagnostics and Research. 61
28791067 2017
42
Sequential NAION presenting as pseudo Foster Kennedy syndrome. 61
28431627 2017
43
Intracranial Pressure Influences the Behavior of the Optic Nerve Head. 61
27935009 2017
44
Assessment of Rod, Cone, and Intrinsically Photosensitive Retinal Ganglion Cell Contributions to the Canine Chromatic Pupillary Response. 61
28061512 2017
45
Normative Spectral Domain Optical Coherence Tomography Data in Healthy Turkish Children. 61
26795877 2017
46
Optic Nerve. 61
27787712 2017
47
Update on the application of optic nerve sheath fenestration. 61
28339414 2017
48
[Pay attention on optical coherence tomography evaluation for optic nerve diseases]. 61
27998452 2016
49
Mesenchymal stem cell therapy in retinal and optic nerve diseases: An update of clinical trials. 61
27928464 2016
50
Transcorneal electrical stimulation promotes survival of retinal ganglion cells after optic nerve transection in rats accompanied by reduced microglial activation and TNF-α expression. 61
27569587 2016

Variations for Foster-Kennedy Syndrome

Expression for Foster-Kennedy Syndrome

Search GEO for disease gene expression data for Foster-Kennedy Syndrome.

Pathways for Foster-Kennedy Syndrome

GO Terms for Foster-Kennedy Syndrome

Cellular components related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.46 SDHD SDHC SDHAF2 SDHA
2 mitochondrial inner membrane GO:0005743 9.13 SDHD SDHC SDHA
3 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.8 SDHD SDHC SDHA

Biological processes related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.43 SDHD SDHC SDHA
2 tricarboxylic acid cycle GO:0006099 9.26 SDHD SDHC SDHAF2 SDHA
3 electron transport chain GO:0022900 9.16 SDHC SDHA
4 mitochondrial electron transport, succinate to ubiquinone GO:0006121 8.92 SDHD SDHC SDHAF2 SDHA

Molecular functions related to Foster-Kennedy Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 9.26 SDHD SDHC
2 oxidoreductase activity, acting on the CH-CH group of donors GO:0016627 9.16 SDHC SDHA
3 electron transfer activity GO:0009055 9.13 SDHD SDHC SDHA
4 succinate dehydrogenase activity GO:0000104 8.8 SDHD SDHC SDHA

Sources for Foster-Kennedy Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....